Ribonexus
Latest round
- Seed
Last raised
- Sep 2021
Total raised
- $2.4M
Investors
- 3
About Ribonexus
Based in France, Aglaia Therapeutics operates as a biotechnology company that creates medicines for cancer patients who are receiving targeted therapy. The company was co-founded by Advent France Biotechnology, Alejo Chorny, and Institut Curie, and Gustave Roussy. The company offers oncology therapies that aim to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who develop resistance to these kinds of treatments. The therapy targets mRNA translation through an acquisition of a product from Pierre Fabre.
Who invested in Ribonexus
3 investors across 1 round
See all investors in Ribonexus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Sep 10, 2021
Amount
$2.4M
Investors
Questions about Ribonexus
Who invested in Ribonexus?
Ribonexus has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ribonexus raised?
Ribonexus has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ribonexus last raise money?
Ribonexus's most recent round on record is a Seed, in Sep 2021.
What does Ribonexus do?
Based in France, Aglaia Therapeutics operates as a biotechnology company that creates medicines for cancer patients who are receiving targeted therapy.
Where is Ribonexus headquartered?
Ribonexus is headquartered in France.
Which VCs invest in companies like Ribonexus?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Ribonexus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Ribonexus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.